

PRESS RELEASE

Stockholm, Sweden, 31 January 2019



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 31 January 2019, the total number of shares in [Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) amounts to 297,515,209 shares. All shares are common shares. The total number of votes is 297,515,209. The increase in the number of shares and votes results from an issue of 24,193,092 common shares. The common shares have been issued in connection with the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US. As per 31 January 2019 the company holds 3,423,726 common shares.

About Sobi™

Sobi™ is an international biopharmaceutical company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations/Investor relations

Linda Holmström, Senior Communications/IR Manager

+46 708 734 095

linda.holmstrom@sobi.com

Investor relations

Jörgen Winroth, Senior IR Advisor

+1 347 224 0819, +1 212 579 0506

jorgen.winroth@sobi.com

Paula Treutiger, Head of Communications & Investor Relations

+46 733 666 599

paula.treutiger@sobi.com

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 31 January 2019 at 8:30 CET.

Swedish Orphan Biovitrum AB (publ)

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 8 697 20 00 | www.sobi.com